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Abstract: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease driven by genetic,
environmental and epigenetic factors. Long non-coding RNAs (LncRNAs) are a key component of the
epigenetic mechanisms and are known to be involved in the development of autoimmune diseases.
In this work we aimed to identify significantly differentially expressed LncRNAs (DE-LncRNAs) that
are functionally connected to modulated genes strictly associated with RA. In total, 542,500 transcripts
have been profiled in peripheral blood mononuclear cells (PBMCs) from four patients with early onset
RA prior any treatment and four healthy donors using Clariom D arrays. Results were confirmed by
real-time PCR in 20 patients and 20 controls. Six DE-LncRNAs target experimentally validated miRNAs
able to regulate differentially expressed genes (DEGs) in RA; among them, only FTX, HNRNPU-AS1
and RP11-498C9.15 targeted a large number of DEGs. Most importantly, RP11-498C9.15 targeted
the largest number of signalling pathways that were found to be enriched by the global amount
of RA-DEGs and that have already been associated with RA and RA–synoviocytes. Moreover,
RP11-498C9.15 targeted the most highly connected genes in the RA interactome, thus suggesting its
involvement in crucial gene regulation. These results indicate that, by modulating both microRNAs
and gene expression, RP11-498C9.15 may play a pivotal role in RA pathogenesis.
Keywords: long non-coding RNA; microRNA; protein-protein interaction network; gene module
1. Introduction
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of
the joints with severe pain and swelling, joint damage and disability, which ultimately leads to joint
destruction and loss of function [1]. Several genome-wide association studies have identified genetic
variants that confer RA risk. However, these variants can explain less than 20% of susceptibility in RA.
Several factors have been shown to contribute to the onset of the disease, such as genetic susceptibility,
environmental factors including smoking, and epigenetic mechanisms [2].
LncRNAs are epigenetic regulators of gene expression and are involved in immune and
inflammatory molecular networks. Moreover, it has been demonstrated that they also play a role in
several autoimmune diseases [3].
The modulation of some lncRNAs has been described in RA [4], but the interplay between
lncRNAs and gene modulation in RA has only been partially explored. Indeed, only a few microarray
studies described the gene expression profiling analysis of a congruous number of lncRNAs and mRNA
transcripts in RA PBMCs [5,6], but in these works, only target prediction methods were used to inspect
all the possible interactions among lncRNAs and coding genes. Moreover, only lncRNA-mRNA pairs
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that were simply co-expressed or that are simply transcribed from nearby loci have been considered.
Thus, despite these notable reports, the role of lncRNA in modulating RA pathogenesis remains unclear.
Notably, it has been demonstrated that lncRNAs can also modulate gene expression by sponging
microRNAs, thus limiting the amount of miRNAs available to target mRNAs. The framework of
regulatory networks must be taken into account in evaluating the potential of lncRNAs for tuning
gene expression profiles.
In the present work we aimed to identify lncRNAs modulated in RA patients in order to evaluate
whether they are involved in disease-associated gene modulation, only taking into account their
experimentally validated gene targets. Moreover, we have analysed the complex network of molecular
interactions among coding and non-coding transcripts (i.e., lncRNAs and miRNAs, that may be
involved in RA pathogenesis.
2. Materials and Methods
2.1. Patients
To perform the gene array analysis we enrolled four patients, two females and two males,
mean age 54 ± 15 affected by early rheumatoid arthritis, defined by the presence of positive rheumatoid
factor and/or anti-citrullinated protein antibodies, of increased ESR and/or CRP, of synovitis (detected
by physical examination and musculoskeletal ultrasound), lasting more than six weeks and less
than six months, and by the number of small tender or swollen joints. Patients fulfilled the 2010
American College of Rheumatology/European League against Rheumatism classification criteria for
RA [7]. Twelve additional patients and healthy subjects were enrolled for the RT-PCR validation test.
The clinical characteristics of these patients were similar to those of the patients used for the gene
array analysis. Patients were not treated with conventional disease-modifying antirheumatic drugs,
biologicals, or prednisolone. Nonsteroidal anti-inflammatory drugs were allowed. Enrolled patients
did not suffer from extra-articular manifestations.
Both patients and controls were subjects of Caucasian origin from Northern Italy.
Written informed consent was obtained from all the participants to the study and the study
protocol was approved by the Ethical Committee of the Azienda Ospedaliera Universitaria Integrata
di Verona (identification code 1538, date of approval 23 April 2008). All the investigations have been
performed according to the principles contained in the Helsinki declaration.
2.2. Microarray Analysis
Blood sample collection was carried out using BD Vacutainer K2EDTA tubes (Becton Dickinson,
Franklin Lakes, NJ, USA) and 21-gauge needles.
PBMCs isolation was performed by Ficoll-HyPaque (Pharmacia Biotech, Quebec, Canada) gradient
centrifugation. Patients and controls had a similar PBMCs distribution. Total RNA was extracted
from PBMCs (107 cells) using an miRNeasy mini kit (Qiagen GmbH, Hilden, Germany). cRNA
preparation, sample hybridization and scanning were performed following the protocols provided by
Affymetrix (Santa Clara, CA, USA), using a Cogentech Affymetrix microarray unit (Campus IFOM
IEO, Milan, Italy). All samples were hybridized on a Human Clariom D (Thermo Fisher Scientific,
Waltham, MA, USA) gene chip. Signal intensities were analysed with Transcriptome Analysis Console
(TAC) 4.0 software (Applied Biosystems, Foster City, CA, USA).
Using the Human Clariom D arrays, more than 540,000 human transcripts can be interrogated,
starting from as little as 100 pg of total RNA. The signal intensity was background-adjusted,
normalized and log-transformed using the signal space transformation (SST)-robust multi-array
average algorithm (RMA).
Differentially expressed genes that showed an expression level at least 1.5-fold different in the
test sample versus a control sample at a significant level (FDR corrected p-value ≤ 0.05) were chosen
for final consideration. Target annotations of long non-coding RNAs were retrieved using starBase
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v2.0 (http://starbase.sysu.edu.cn/starbase2/index.php), where lncRNAs interactions, experimentally
validated by high-throughput experimental technologies, are registered [8].
The list of gene targets of microRNAs (miRNAs) that are targeted by lncRNAs was gathered from
the FunRich database (http://www.funrich.org/) [9].
2.3. Protein-Protein Interaction (PPI) Network Construction and Network Clustering
The PPI network was constructed upon the experimentally validated protein-protein interactions
using STRING (Search Tool for the Retrieval of Interacting Genes) version 10.5 (http://string-db.org/) [10].
Network topological analysis was performed using Cytoscape software (http://www.cytoscape.org/) [11].
High-flow areas (highly connected regions) of the network (modules) were detected using the MCODE
plugin of Cytoscape (k-core = 4 and node score cutoff = 0.2).
2.4. Gene Functional Classification and Enrichment Analysis
Genes were functionally classified into biological processes (BPs) according to the Gene Ontology
(GO) annotations (http://www.geneontology.org/) [12] by the Panther expression analysis tools
(http://pantherdb.org/) [13].
Pathway classification and enrichment (Bonferroni corrected p-value≤ 0.05) analysis were achieved
with FunRich.
2.5. Real-Time PCR of LncRNA
First, 500 ng of total RNA were treated with one unit of DNase I Amplification Grade (Invitrogen,
Carlsbad, CA, USA). First-strand cDNA was generated using the SuperScript IV First-Strand Synthesis
System (Invitrogen) with random hexamers, according to the manufacturer’s protocol. Real-time
PCR was performed in triplicate with a PowerUp™ Sybr® Green reagent (Applied Biosystems) in a
QuantStudio 6 Flex system (Applied Biosystems). Transcripts’ relative expression levels were obtained
after normalization against the geometric mean of the housekeeping genes GAPDH and beta-actin
(ACTB) expression. The ∆∆Ct method was used for comparing relative fold expression differences.
Results are expressed as fold changes with respect to healthy patients.
2.6. Real-Time PCR of Genes Modulated in RA Patients
First-strand cDNA was obtained using the SuperScript III First-Strand Synthesis System for
RT-PCR Kit (Invitrogen), with random hexamers, following the manufacturer’s protocol. PCR was
performed in a total volume of 25 µL containing 1× Taqman Universal PCR Master mix, no AmpErase
UNG and 2.5 µL of cDNA; pre-designed, Gene-specific primers and probe sets for each gene were
obtained from Assay-on-Demand Gene Expression Products service (Applied Biosystems).
Real-time PCR reactions were carried out in a two-tube system and in singleplex. The real-time
amplifications encompassed 10 min at 95 ◦C (AmpliTaq Gold activation), followed by 40 cycles at
95 ◦C for 15 s and at 60 ◦C for 1 min. Thermocycling and signal detection were performed with a
7500 Sequence Detector (Applied Biosystems). Signals were detected by following the manufacturer’s
instructions. This methodology allows for the identification of the cycling point where the PCR product
is detectable by means of fluorescence emission (threshold cycle or Ct value). The Ct value correlates
to the quantity of target mRNA. Relative expression levels were calculated for each sample after
normalization against the housekeeping genes GAPDH, beta-actin and 18s ribosomal RNA (rRNA),
using the ∆∆Ct method for comparing relative fold expression differences. Ct values for each reaction
were determined using TaqMan SDS analysis software (Applied Biosystems). For each amount of
RNA tested, triplicate Ct values were averaged. Since Ct values vary linearly with the logarithm of the
amount of RNA, this average represents a geometric mean.
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2.7. Real-Time PCR of MicroRNA
miRNA expression was evaluated by TaqMan® Advanced miRNA assays chemistry (Applied
Biosystems). Briefly, 10 ng of total RNA was reverse transcribed and pre-amplified with TaqMan®
Advanced miRNA cDNA synthesis kit according to the manufacturer’s instructions (Applied
Biosystems). Pre-amplified cDNA was diluted 1/10 in nuclease-free water and 5 µL of diluted
cDNA for each replicate were loaded in PCR. 20 µL PCR reactions were composed by 2× Fast Advanced
Master Mix and TaqMan® Advanced miRNA assay for miR-520e. The mean of Ct for hsa-miR-16-5p
and hsa-miR-26a-5p expression was used to normalize miRNA expression. Real-time PCR was carried
out in triplicate on a QuantStudio 6 Flex instrument (Applied Biosystems). Expression values were
reported as fold change with respect to healthy controls by the ∆∆Ct method, employing QuantStudio
Real-Time PCR system software v. 1.3.
2.8. Statistical Analysis
Statistical testing was performed using SPSS Statistics 2 software (IBM, Armonk, NY, USA).
Data obtained from RT-PCR analysis of RA samples and healthy controls were analysed using the
Mann-Whitney Test.
3. Results
3.1. High-Throughput Gene and Long Non-Coding RNA Expression Profiling in Peripheral Blood Mononuclear
Cells of RA Patients
We simultaneously profiled the expression of more than 540,000 human transcripts, including those
ascribed to more than 50,000 long non-coding RNAs (lncRNAs), in four PBMC samples from patients
with clinically diagnosed RA symptoms, with the purpose of identifying lncRNAs potentially involved
in RA pathogenesis. RA-associated transcriptional profiles were compared to those obtained from four
age- and sex-matched healthy subjects and, 97 lncRNAs and 942 coding genes were selected applying
a robust filtering approach (FDR-corrected p-value ≤ 0.05 and fold change ≥ |1.5|) (Tables S1 and S2).
The functional classification by Gene Ontology (http://www.geneontology.org/) of
the 942 differentially expressed genes (DEGs) highlighted the modulation of transcripts that play a role
in biological processes (BPs) strictly associated with RA, including apoptosis, cell proliferation,
cell migration, inflammatory response, immune response, angiogenesis, extracellular matrix
degradation and bone resorption. In particular, we observed that the bone resorption BP included
upregulated genes that negatively regulate osteoblast functions, such as HES1, and genes that are
involved in osteoclast development, like ATP6AP1, TCTA and SBNO2 [14–16]. In this regard, we also
have to mention the upregulation of CSF1/MG-CSF that is one of the most important soluble factors
responsible for osteoclast maturation and survival [17]. Interestingly, PLCB1, a positive regulator of
osteoblast differentiation [18], was downregulated in RA samples.
Several DEGs were involved in well-known pathways including Wnt, TNF, type I interferon,
p38 MAP kinase, NF-kB, Toll-like receptors, Jak-Stat, PI3K and mTOR signalling that have already been
associated with RA pathogenesis. A selection of genes involved in the abovementioned functional
classes is given in Tables 1 and 2.
Table 1. Selected biological processes in which genes modulated in RA are involved.
ID FoldChange
FDR
p-Value
Gene
Symbol Description
mRNA
Accession
Apoptosis
TC0300009843.hg.1 2.12 0.050 TP63 tumour protein p63 NM_001114978
TC2200007783.hg.1 5.34 0.008 PIM3 Pim-3 proto-oncogene, serine/threonine kinase NM_001001852
TC0300010770.hg.1 12.5 0.008 CSRNP1 cysteine-serine-rich nuclear protein 1 NM_033027
TC1900009429.hg.1 2.3 0.018 KHSRP KH-type splicing regulatory protein NM_003685
TC0600011441.hg.1 3.47 0.008 BAG6 BCL2-associated athanogene 6 NM_001199697
TC1100013230.hg.1 2.08 0.023 BCL9L B-cell CLL/lymphoma 9-like NM_182557
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Table 1. Cont.
ID FoldChange
FDR
p-Value
Gene
Symbol Description
mRNA
Accession
Apoptosis
TC0100007449.hg.1 2.2 0.049 SH3BGRL3 SH3 domain binding glutamate-rich protein like 3 NM_031286
TC1100006815.hg.1 3 0.037 WEE1 WEE1 G2 checkpoint kinase NM_001143976
Cell proliferation
TC0300009702.hg.1 2.49 0.044 EIF4G1 eukaryotic translation initiation factor 4 gamma, 1 NM_001194946
TC0X00007132.hg.1 3.18 0.008 CDK16 cyclin-dependent kinase 16 NM_001170460
TC0200015764.hg.1 3.79 0.004 CNPPD1 cyclin Pas1/PHO80 domain containing 1 NM_015680
TC0200016494.hg.1 2.04 0.046 CNNM4 cyclin and CBS domain divalent metal cationtransport mediator 4 NM_020184
TC1900010696.hg.1 5.13 0.007 AKT2 v-akt murine thymoma viral oncogene homolog 2 NM_001243027
Cell migration
TC1500010018.hg.1 2.3 0.018 SEMA7A semaphorin 7A, GPI membrane anchor NM_001146029
TC1200012859.hg.1 3.65 0.006 RHOF ras homolog family member F (in filopodia) NM_019034
TC1100009864.hg.1 3.29 0.004 RHOG ras homolog family member G NM_001665
TC1700009528.hg.1 2.46 0.028 CXCL16 chemokine (C-X-C motif) ligand 16 NM_001100812
Inflammatory response
TC1500006925.hg.1 24.36 0.018 THBS1 thrombospondin 1 NM_003246
TC1900006977.hg.1 11.9 0.050 ICAM1 intercellular adhesion molecule 1 NM_000201
TC0500007231.hg.1 3.28 0.022 PTGER4 prostaglandin E receptor 4 (subtype EP4) NM_000958
TC0100011384.hg.1 2.52 0.025 MAPKAPK2 mitogen-activated protein kinase-activated proteinkinase 2 NM_004759
TC0100009364.hg.1 3.82 0.008 CSF1 colony stimulating factor 1 (macrophage) NM_000757
TC0300006985.hg.1 6.3 0.034 CCR4 chemokine (C-C motif) receptor 4 NM_005508
TC1900010743.hg.1 2.7 0.019 TGFB1 transforming growth factor beta 1 NM_000660
TC1000007990.hg.1 4.92 0.020 DDIT4 DNA damage inducible transcript 4 NM_019058
TC1600011060.hg.1 2.28 0.017 COTL1 coactosin-like F-actin binding protein 1 NM_021149
TC2000009401.hg.1 3.54 0.011 SPATA2 Spermatogenesis-associated 2 NM_00113577
TC1100011243.hg.1 4.25 0.007 RELA v-rel avian reticuloendotheliosis viral oncogenehomolog A NM_001145138
TC0900011623.hg.1 2.16 0.030 PTGES2 prostaglandin E synthase 2 NM_001256335
TC0200014672.hg.1 7.65 0.042 NR4A2 nuclear receptor subfamily 4, group A, member 2 NM_006186
TC1900007270.hg.1 6.2 0.007 KLF2 Kruppel-like factor 2 NM_016270
TC1700011903.hg.1 4.41 0.046 SOCS3 suppressor of cytokine signalling 3 NM_003955
TC1600009395.hg.1 3.76 0.010 SOCS1 suppressor of cytokine signalling 1 NM_003745
TC0100017107.hg.1 2.71 0.041 IL10 interleukin 10 NM_000572
TC1100009225.hg.1 7.04 0.006 CXCR5 chemokine (C-X-C motif) receptor 5 NM_001716
TC1100013178.hg.1 2.22 0.023 MAP4K2 mitogen-activated protein kinase kinase kinasekinase 2 NM_001307990
TC1700007262.hg.1 4.43 0.023 MAP2K3 mitogen-activated protein kinase kinase 3 NM_002756
TC1900009325.hg.1 3.56 0.038 MAP2K2 mitogen-activated protein kinase kinase 2 NM_030662
TC0600011438.hg.1 2.07 0.045 LTB lymphotoxin beta (TNF superfamily, member 3) NM_002341
TC1700011903.hg.1 4.41 0.046 SOCS3 suppressor of cytokine signalling 3 NM_003955
Immune response
TC0200008452.hg.1 2.85 0.024 MAL mal, T-cell differentiation protein NM_002371
TC1100006576.hg.1 3.74 0.015 CD81 CD81 molecule NM_001297649
TC0600007495.hg.1 2.08 0.037 HLA-A major histocompatibility complex, class I, A NM_001242758
TC0100007291.hg.1 2.08 0.028 C1QC complement component 1, q subcomponent,C chain NM_001114101
TC1100007787.hg.1 3.29 0.035 CD6 CD6 molecule NM_001254750
TC1600011368.hg.1 3.14 0.008 LAT linker for activation of T-cells NM_001014987
TC1900008279.hg.1 5.58 0.006 BCL3 B-cell CLL/lymphoma 3 NM_005178
TC1900008166.hg.1 3.13 0.004 CD79A CD79a molecule,immunoglobulin-associated alpha NM_001783
TC1200010950.hg.1 2.47 0.034 STAT6 signal transducer and activator of transcription 6,interleukin-4 induced NM_001178078
TC1000008891.hg.1 10.97 0.008 DUSP5 dual specificity phosphatase 5 NM_004419
TC0600008972.hg.1 5.51 0.018 PRDM1 PR domain containing 1, with ZNF domain NM_001198
TC0100016000.hg.1 4.15 0.004 MEF2D myocyte enhancer factor 2D NM_001271629
TC0900008891.hg.1 2.21 0.023 LRRC8A leucine rich repeat containing 8 family, member A NM_001127244
TC1900009320.hg.1 2.71 0.045 ZBTB7A zinc finger and BTB domain containing 7A NM_015898
TC1900008505.hg.1 2.93 0.018 BAX BCL2-associated X protein NM_001291428
TC1800007805.hg.1 2.22 0.027 NFATC1 nuclear factor of activated T-cells, cytoplasmic,calcineurin-dependent 1 NM_001278669
TC2200008637.hg.1 3.64 0.015 IL2RB interleukin 2 receptor, beta NM_000878
Angiogenesis
TC1200010839.hg.1 2 0.029 ITGA5 integrin alpha 5 NM_002205
TC2000007336.hg.1 2.83 0.015 PPP1R16B protein phosphatase 1, regulatory subunit 16B NM_001172735
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Table 1. Cont.
ID FoldChange
FDR
p-Value
Gene
Symbol Description
mRNA
Accession
Angiogenesis
TC1600008971.hg.1 2.83 0.018 JMJD8 jumonji domain containing 8 NM_001005920
TC1700011818.hg.1 2.6 0.050 JMJD6 jumonji domain containing 6 NM_001081461
TC0100007832.hg.1 17.12 0.008 ZC3H12A zinc finger CCCH-type containing 12A NM_025079
TC0100018300.hg.1 2.44 0.032 ADAM15 ADAM metallopeptidase domain 15 NM_001261464
Bone resorption
Positive regulation of bone resorption
TC0X00008831.hg.1 2.62 0.021 ATP6AP1 ATPase, H+ transporting, lysosomal accessoryprotein 1 NM_001183
TC2000007283.hg.1 2.11 0.026 SRC SRC proto-oncogene, non-receptor tyrosine kinase NM_005417
TC0300009916.hg.1 4.17 0.030 HES1 hes family bHLH transcription factor 1 NM_005524
TC0100015891.hg.1 2.76 0.008 CRTC2 CREB regulated transcription coactivator 2 NM_181715
TC1900010009.hg.1 3.41 0.023 JUND jun D proto-oncogene NM_001286968
Positive regulation of osteoclast proliferation/differentiation
TC0300007380.hg.1 2.4 0.027 TCTA T-cell leukaemia translocation altered NM_022171
TC1900009134.hg.1 9.56 0.002 SBNO2 strawberry notch homolog 2 NM_014963
TC0100009364.hg.1 3.82 0.008 CSF1 colony stimulating factor 1 (macrophage) NM_000757
TC0X00008831.hg.1 2.62 0.021 ATP6AP1 ATPase, H+ transporting, lysosomal accessoryprotein 1 NM_001183
TC0300009916.hg.1 4.17 0.030 HES1 hes family bHLH transcription factor 1 NM_005524
TC0500007231.hg.1 3.28 0.022 PTGER4 prostaglandin E receptor 4 (subtype EP4) NM_000958
TC1900007096.hg.1 5.16 0.032 JUNB jun B proto-oncogene NM_002229
Osteoblast differentiation
TC2000009887.hg.1 −2.8 0.0172 PLCB1 phospholipase C, beta 1(phosphoinositide-specific) NM_015192
Extracellular matrix degradation
TC2000007514.hg.1 3.14 0.041 MMP9 matrix metallopeptidase 9 NM_004994
TC0500012599.hg.1 1.9 0.040 ADAM19 ADAM metallopeptidase domain 19 NM_033274
TC0100018300.hg.1 2.44 0.032 ADAM15 ADAM metallopeptidase domain 15 NM_001261464
TC1900006470.hg.1 3.01 0.011 BSG basigin NM_001728
Table 2. Selected signalling pathways involving genes modulated in RA.
ID FoldChange
FDR
p-Value
Gene
Symbol Description
mRNA
Accession
Wnt signalling pathway
TC1900009272.hg.1 2.4 0.018 AES amino-terminal enhancer of split NM_001130
TC1100008181.hg.1 2.03 0.029 LRP5 LDL-receptor-related protein 5 NM_001291902
TC0200014672.hg.1 7.65 0.042 NR4A2 nuclear receptor subfamily 4, group A, member 2 NM_006186
TC1100007913.hg.1 2.69 0.048 MARK2 MAP/microtubule affinity-regulating kinase 2 NM_001039469
TC1200007595.hg.1 2.88 0.023 SMARCD1
SWI/SNF-related, matrix-associated,
actin-dependent regulator of chromatin,
subfamily d, member 1
NM_003076
TC1900011639.hg.1 2.1 0.032 STK11 serine/threonine kinase 11 NM_000455
TC1100008181.hg.1 2.03 0.029 LRP5 LDL-receptor-related protein 5 NM_001291902
TNF signalling pathway
TC0900011385.hg.1 −1.99 0.040 PSMD5 proteasome 26S subunit, non-ATPase 5 NM_001270427
TC0600011438.hg.1 2.07 0.045 LTB lymphotoxin beta (TNF superfamily, member 3) NM_002341
TC1700010879.hg.1 2.36 0.026 MAP3K14 mitogen-activated protein kinase kinase kinase 14 NM_003954
TC1600010616.hg.1 2.14 0.035 TRADD TNFRSF1A-associated via death domain NM_003789
TC1100011243.hg.1 4.25 0.007 RELA v-rel avian reticuloendotheliosis viral oncogenehomolog A NM_001145138
Type I interferon signalling
TC0600007495.hg.1 2.08 0.037 HLA-A major histocompatibility complex, class I, A NM_001242758
TC0200008452.hg.1 2.85 0.024 MAL mal, T-cell differentiation protein NM_002371
TC0100017107.hg.1 2.71 0.041 IL10 interleukin 10 NM_000572
TC1600009395.hg.1 3.76 0.010 SOCS1 suppressor of cytokine signalling 1 NM_003745
TC1100011243.hg.1 4.25 0.007 RELA v-rel avian reticuloendotheliosis viral oncogenehomolog A NM_001145138
TC1900009627.hg.1 2.63 0.040 TYK2 tyrosine kinase 2 NM_003331
TC1000008727.hg.1 2.64 0.024 NFKB2 nuclear factor of kappa light polypeptide geneenhancer in B-cells 2 (p49/p100) NM_001077494
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Table 2. Cont.
ID FoldChange
FDR
p-Value
Gene
Symbol Description
mRNA
Accession
p38 MAP kinase signalling
TC1400009524.hg.1 2.91 0.029 ZFP36L1 ZFP36 ring finger protein-like 1 NM_001244698
TC1700007262.hg.1 4.43 0.023 MAP2K3 mitogen-activated protein kinase kinase 3 NM_002756
TC0100011384.hg.1 2.52 0.025 MAPKAPK2 mitogen-activated protein kinase-activated proteinkinase 2 NM_004759
TC0X00009581.hg.1 2.99 0.013 ELK1 ELK1, member of ETS oncogene family NM_001114123
TC0100016000.hg.1 4.15 0.004 MEF2D myocyte enhancer factor 2D NM_001271629
NF-kB signalling pathway
TC1900008300.hg.1 2.78 0.034 RELB v-rel avian reticuloendotheliosis viral oncogenehomolog B NM_006509
TC1900008279.hg.1 5.58 0.006 BCL3 B-cell CLL/lymphoma 3 NM_005178
TC1600010616.hg.1 2.14 0.035 TRADD TNFRSF1A-associated via death domain NM_003789
TC1100011243.hg.1 4.25 0.007 RELA v-rel avian reticuloendotheliosis viral oncogenehomolog A NM_001145138
TC1700010879.hg.1 2.36 0.026 MAP3K14 mitogen-activated protein kinase kinase kinase 14 NM_003954
TC0800012190.hg.1 3.65 0.018 SHARPIN SHANK-associated RH domain interactor NM_030974
TOLL-like receptors signalling pathways
TC0200008452.hg.1 2.85 0.024 MAL mal, T-cell differentiation protein NM_002371
TC0X00009581.hg.1 2.99 0.013 ELK1 ELK1, member of ETS oncogene family NM_001114123
TC0100011384.hg.1 2.52 0.025 MAPKAPK2 mitogen-activated protein kinase-activated proteinkinase 2 NM_004759
TC1000008727.hg.1 2.64 0.024 NFKB2 nuclear factor of kappa light polypeptide geneenhancer in B-cells 2 NM_001077494
TC1700007262.hg.1 4.43 0.023 MAP2K3 mitogen-activated protein kinase kinase 3 NM_002756
TC1100011243.hg.1 4.25 0.007 RELA v-rel avian reticuloendotheliosis viral oncogenehomolog A NM_001145138
Jak-Stat signalling pathway
TC1600009395.hg.1 3.76 0.010 SOCS1 suppressor of cytokine signalling 1 NM_003745
TC1700011903.hg.1 4.41 0.046 SOCS3 suppressor of cytokine signalling 3 NM_003955
TC1900009991.hg.1 2.63 0.042 JAK3 Janus kinase 3 NM_000215
TC1200010950.hg.1 2.47 0.034 STAT6 signal transducer and activator of transcription 6,interleukin-4 induced NM_001178078
PI3K signalling pathway
TC1900010696.hg.1 5.13 0.007 AKT2 v-akt murine thymoma viral oncogene homolog 2 NM_001243027
TC1100008136.hg.1 2.31 0.023 RPS6KB2 ribosomal protein S6 kinase, 70kDa, polypeptide 2 NM_003952
TC1000007990.hg.1 4.92 0.020 DDIT4 DNA damage inducible transcript 4 NM_019058
TC1000008891.hg.1 10.97 0.008 DUSP5 dual specificity phosphatase 5 NM_004419
TC0700008560.hg.1 3.76 0.026 GNB2 guanine nucleotide binding protein (G protein),beta polypeptide 2 NM_005273
TC1900010009.hg.1 3.41 0.023 JUND jun D proto-oncogene NM_001286968
TC1900007096.hg.1 5.16 0.032 JUNB jun B proto-oncogene NM_002229
TC0600008972.hg.1 5.51 0.018 PRDM1 PR domain containing 1, with ZNF domain NM_001198
mTOR signalling pathway
TC0300013684.hg.1 2.21 0.043 TFRC transferrin receptor NM_001128148
TC1200007595.hg.1 2.88 0.023 SMARCD1
SWI/SNF-related, matrix-associated,
actin-dependent regulator of chromatin,
subfamily d, member 1
NM_003076
TC1700011903.hg.1 4.41 0.046 SOCS3 suppressor of cytokine signalling 3 NM_003955
TC2000007283.hg.1 2.11 0.026 SRC SRC proto-oncogene, non-receptor tyrosine kinase NM_005417
TC0400009765.hg.1 3.06 0.018 MXD4 MAX dimerization protein 4 NM_006454
TC0100016000.hg.1 4.15 0.004 MEF2D myocyte enhancer factor 2D NM_001271629
All the differentially expressed transcripts were submitted to a pathway enrichment analysis
that highlighted other meaningful signalling networks in which modulated genes were involved.
These pathways included, for example, signalling that operates in vascular biology (i.e., PAR, uPA/uPAR,
PDGFR, endothelins and VEGF signalling), interferon-gamma, EGF-receptor, Arf6, IL-5, IL-3 and S1P1
signalling pathways. All the enriched pathways (Bonferroni corrected p-value ≤ 0.05) are listed in
Table 3.
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Table 3. Signalling pathways significantly enriched in genes modulated in RA patients.
Biological Pathway Bonferroni Corrected p-Value
Proteoglycan syndecan-mediated signalling events 0.006
Alpha9 beta1 integrin signalling events 0.020
GMCSF-mediated signalling events 0.025
Beta1 integrin cell surface interactions 0.026
IL3-mediated signalling events 0.027
IFN-gamma pathway 0.028
PAR1-mediated thrombin signalling events 0.031
Thrombin/protease-activated receptor (PAR) pathway 0.032
Syndecan-1-mediated signalling events 0.032
Integrin family cell surface interactions 0.032
Plasma membrane oestrogen receptor signalling 0.033
Endothelins 0.040
Signalling events mediated by focal adhesion kinase 0.040
PDGFR-beta signalling pathway 0.040
Arf6 trafficking events 0.040
Class I PI3K signalling events mediated by Akt 0.040
mTOR signalling pathway 0.040
Internalization of ErbB1 0.040
EGF receptor (ErbB1) signalling pathway 0.040
Class I PI3K signalling events 0.040
Arf6 signalling events 0.040
ErbB1 downstream signalling 0.040
Arf6 downstream pathway 0.040
Insulin Pathway 0.040
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signalling 0.040
S1P1 pathway 0.040
EGFR-dependent Endothelin signalling events 0.041
IGF1 pathway 0.044
ErbB receptor signalling network 0.045
Sphingosine 1-phosphate (S1P) pathway 0.045
IL5-mediated signalling events 0.045
Signalling events mediated by hepatocyte growth factor receptor (c-Met) 0.047
PDGF receptor signalling network 0.047
Nectin adhesion pathway 0.049
Signalling events mediated by VEGFR1 and VEGFR2 0.051
Glypican 1 network 0.056
Glypican pathway 0.055
VEGF and VEGFR signalling network 0.055
Integrin-linked kinase signalling 0.053
3.2. Selected Long Non-Coding RNAs Modulated in RA Patients Have the Potential to Regulate Genes
Differentially Expressed in the Disease
To strengthen the significance of our analysis, we interrogated the StarBase database to select only
modulated lncRNAs for which experimentally validated microRNA (miRNA) targets had already
been annotated and, by this criterion, six out of 97 lncRNAs were filtered: FTX, HNRNPU-AS1,
MIATNB, RP11-498C9.15, RP4-714D9.5 and RP11-73E17.2. All these lncRNAs were downregulated
except RP11-498C9.15 and RP11-73E17.2, which were overexpressed in RA samples (Table 4).
To find all the possible interactions among modulated genes and the selected lncRNAs, we verified
if they could target miRNAs able to regulate RA-DEGs. We therefore analysed the complete list of
genes regulated by the miRNA targets of the six lncRNA that were validated by high-throughput
technologies, and selected only those microRNAs that could modulate differentially expressed genes
in RA patients. We thus observed that all the selected lncRNAs, via their miRNA targets, could
control genes differentially expressed in RA patients, but only FTX, HNRNPU-AS1 and RP11-498C9.15
targeted quite a large number of DEGs (Tables 4 and S3).
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Table 4. Selected lncRNAs modulated in RA patients.
ID FoldChange
FDR
p-Value Gene Symbol mRNA Accession
miRNA
Targets
Targeted
Modulated
Genes
TC0X00010064.hg.1 −2.03 0.049 FTX NR_028379 64 96
TC0100018570.hg.1 −2.64 0.034 HNRNPU-AS1 NR_026778 55 161
TC2200009240.hg.1 −2 0.042 MIATNB NR_110543 16 11
TC1700012077.hg.1 2.5 0.039 RP11-498C9.15 ENST00000582866.1 27 106
TC0100009198.hg.1 −3.23 0.008 RP4-714D9.5 ENST00000564623.1 6 27
TC1400006883.hg.1 2.74 0.018 RP11-73E17.2 ENST00000557373.1 1 4
To gain insight on the potential role played by the selected lncRNAs in regulating gene clusters that
were most probably associated with the disease pathogenesis, we performed a pathways enrichment
analysis of all their targeted DEGs. This approach led us to observe that genes targeted by RP11-498C9.15
significantly enriched (Bonferroni p-value < 0.05) the largest number of signalling pathways and,
interestingly, these pathways were almost the same as those that were globally enriched by the
942 modulated genes (Table 5). On the contrary, FTX and HNRNPU-AS1 targeted a small number of
enriched pathways that were also targeted by RP11-498C9.15, whereas MIATNB RP4-714D9.5 and
RP11-73E17.2 did not target any enriched pathways (Table S4). These results led us to suppose that
RP11-498C9.15 may exert a major impact on gene modulation associated with RA so, to examine
its possible involvement in the disease pathogenesis, we focused our analysis on genes targeted by
this lncRNA.
Table 5. Signalling pathways enriched in RA-DEGs that are targeted by RP11-498C9.15.
Biological Pathway Bonferroni Corrected p-Value
Beta1 integrin cell surface interactions 0.004
Integrin family cell surface interactions 0.006
IFN-gamma pathway 0.008
PAR1-mediated thrombin signalling events 0.008
Thrombin/protease-activated receptor (PAR) pathway 0.009
Plasma membrane oestrogen receptor signalling 0.009
Endothelins 0.009
Glypican pathway 0.014
Proteoglycan syndecan-mediated signalling events 0.016
Signalling events mediated by focal adhesion kinase 0.030
Class I PI3K signalling events mediated by Akt 0.030
Internalization of ErbB1 0.030
Arf6 downstream pathway 0.030
Arf6 trafficking events 0.030
EGF receptor (ErbB1) signalling pathway 0.030
Urokinase-type plasminogen activator (uPA) and uPAR-mediated
signalling 0.030
ErbB1 downstream signalling 0.030
S1P1 pathway 0.030
Arf6 signalling events 0.030
mTOR signalling pathway 0.030
Insulin pathway 0.030
PDGFR-beta signalling pathway 0.030
Class I PI3K signalling events 0.030
EGFR-dependent Endothelin signalling events 0.030
IGF1 pathway 0.031
GMCSF-mediated signalling events 0.031
IL5-mediated signalling events 0.031
Signalling events mediated by hepatocyte growth factor receptor (c-Met) 0.032
PDGF receptor signalling network 0.032
IL3-mediated signalling events 0.032
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Table 5. Cont.
Biological Pathway Bonferroni Corrected p-Value
Nectin adhesion pathway 0.032
Signalling events mediated by VEGFR1 and VEGFR2 0.033
Glypican 1 network 0.034
Syndecan-1-mediated signalling events 0.035
VEGF and VEGFR signalling network 0.036
Alpha9 beta1 integrin signalling events 0.037
Sphingosine 1-phosphate (S1P) pathway 0.040
ErbB receptor signalling network 0.040
Integrin-linked kinase signalling 0.045
We observed that several DEGs that were targeted by RP11-498C9.15 were involved in meaningful
biological settings, such as the immune and inflammatory response, bone metabolism, apoptosis
regulation, etc. (Figure 1). Moreover, the modulation of several of them has already been associated
with RA. Upregulated targeted genes were, for example, implicated in T cell survival (DUSP5) [19] or
activation (i.e., MAL, LAT and CD81) [20–22], whereas others were involved in B cell development
(i.e., PRDM1/BLIMP-1, MEF2D, LRRC8A and ZBTB7A) [23–25]. Notably, CD81 has been found to be
upregulated in RA synoviocytes [26], while single-nucleotide polymorphisms of the gene BLIMP-1
have already been described in RA [23].
Figure 1. Biological processes involving modulated genes targeted by RP11-498C9.15 in patients
with RA.
A fair number of targeted genes played a role in the inflammatory response, like DDIT4/REDD-1,
COTL1/CLP, SPATA2, PTGER4, PTGES2, NR4A2, LTB and KLF2. Among these, the pro-inflammatory
gene DDIT4 has a role in NF-kB activation [27], which has been shown to modulate the production
of inflammatory cytokines implicated in RA joint pathology [28]. SPATA2 is a component of the
TNF-alpha signalling [29], while COTL1 is able to regulate the production of leukotriene A4 [30] and
NR4A2 and LTB are highly expressed in inflamed RA synovial tissues [31,32]. The gene product of
PTGES2 converts prostaglandin H2 to prostaglandin E2, whereas PTGER4 encode for the prostaglandin
E2 receptor and, interestingly, this molecule is involved in the differentiation and expansion of T helper
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lymphocytes, a process that is involved in RA onset [33]. In addition, this molecule exerts an inhibitory
action on human bone marrow stromal cells-mediated bone matrix mineralization [34].
Notably, other upregulated targeted genes included transcripts that are involved in bone erosion,
like CRTC2, a negative regulator of BMP2-induced osteogenic cell differentiation [35], and JUNB,
involved in osteoclast development [36] and strongly expressed in RA fibroblast-like cells [37].
In addition, it has been demonstrated that JUNB promotes Th17 cells’ development, but inhibits T
regulatory cells’ fate during chronic autoimmunity [38].
We also observed that RP11-498C9.15 targeted upregulated genes involved in the negative control
of the apoptotic process (i.e., SH3BGRL3 and WEE1) and in autophagy (i.e., ATG4D), a mechanism
that seems to be implicated in apoptosis resistance in RA as well as in the development of several
autoimmune diseases including RA [39]. Interestingly, RP11-498C9.15 targeted FOXJ3 and gene
polymorphism of this transcript have been associated with RA [40].
3.3. LncRNA RP11-498C9.15 Targets RA-Associated Meaningful Signalling Pathways
Since, as mentioned above, DEGs targeted by RP11-498C9.15 enriched signalling pathways that
were also over-represented in the whole RA dataset, we analysed the entire list of these molecular
networks (Table 5) and found that almost all are involved in pathogenetic mechanisms that may play a
role in the development of RA and, interestingly, that the activation of several of them has already been
associated with RA pathogenesis. Indeed, the involvement of phosphatidylinositide-3-kinase (PI-3K),
AKT, mTOR and sphingosine-1 phosphate (S1P1) signalling in RA pathogenesis has been extensively
documented [41,42].
The most enriched pathway was the beta-1 integrin signalling, a cluster of molecules that are well
represented at the synovial lining layer, where synovial cells adhere to cartilage. It has been observed
that the RA-associated pro-inflammatory milieu promotes the synthesis of beta-1 integrins [43] and
indeed, fibroblast, macrophages and endothelial cells of RA synovial tissue express high levels of
these molecules. Notably, the beta-1 integrin binding to laminin at the synovial lining, strongly
increases the expression of metalloproteases [43] and signalling by beta-1 integrins leads to immune
cell activation, stimulates cell migration, cytokine production and new vessels formation. Besides the
integrins pathway, interferon-gamma was the second most enriched signalling—not surprising since
this cytokine is rapidly accumulated in RA synovial tissue by activated T cells and its level of expression
correlates with the RA radiographic severity [44].
Pathways involved in vascular biology were also significantly enriched in DEGs modulated by
RP11-498C9.15, including “PAR1-mediated thrombin signalling events,” “urokinase-type plasminogen
activator (uPA)/uPAR-mediated signalling,” and “endothelins” signalling; indeed, it is well known
that RA patients have generalized vasculopathy and finger blood flow abnormalities.
A high level of thrombin activity has been found in RA patients, and it has been suggested that
this molecule may have a strong mitogenic effect on synovial fibroblast-like cells, thus possibly playing
a significant role in RA pathogenesis. Moreover, it has been observed that the high levels of thrombin
that have been detected in RA synovium are associated with increased expression of platelet derived
growth factor beta (PDGF-b) [45] and, interestingly, its pathway was also enriched. Remarkably,
PDGF receptor activation promotes the RA synoviocytes’ pro-destructive behaviour [46].
RA synovial fibroblasts were reported to express high levels of plasminogen activator and urokinase
(uPA), and a pro-inflammatory role has been hypothesized for this molecule, since anti-inflammatory
glucocorticoids strongly suppress uPA gene expression [47]. Finally, endogenous endothelins are
involved in articular inflammation by modulating inflammatory pain, oedema formation and leukocyte
migration. In addition, an elevated plasma level of endothelin-1 has been observed in RA, which may
be associated with the symptoms of vascular dysregulation frequently observed in RA patients [48].
RP11-498C9.15 also targeted members of the proteoglycan glypican and syndecan pathways,
which are structural molecules thought to govern cell migration, tissue invasion and angiogenesis [49],
thus possibly playing a crucial role in fibroblast-like synoviocytes’ behaviour [50]. Other enriched
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pathways involved in angiogenesis were the signalling of focal adhesion kinases (FAKs), epidermal
growth factor (EGF) receptor and VEGF/VEGF-receptor. The former has been implicated in both
RA inflammatory angiogenesis and in RA synovial fibroblasts’ pro-invasive activity [51,52], whereas
the second is particularly involved in synovial fibroblast proliferation. Indeed, EGF and EGFR
serum concentrations are increased in RA patients compared to healthy subjects [53]. VEGF also has
pro-inflammatory and bone-destructive skills and its level correlates with the RA disease activity [54].
It has been described that RA osteoclasts exhibit increased activity and, interestingly, pathways
involved in bone erosion were also significantly enriched, including Arf6, as well as hepatocyte growth
factor (HGF) signalling. The Arf6 pathway plays an important role in osteoclast maturation [55],
while HGF promotes osteoclast activation and inhibits osteoblast differentiation, thus favouring
bone-erosive processes. Interestingly, plasma levels of this cytokine can predict joint damage in RA [56].
RP11-498C9.15 also targeted enriched pathways involved in glucose metabolism like “insulin”
and “insulin growth factor (IGF1)” signalling. The activation of these pathways may reflect the
abnormal glucose metabolism that characterizes a good percentage of RA patients [57] and has been
correlated with the degree of systemic inflammation [58]. In addition, it has been observed that the
pro-inflammatory cytokine TNF may promote insulin resistance by phosphorylation of the insulin
receptor [59].
Enriched targeted pathways also included the granulocyte-macrophage colony-stimulating
factor (GM-CSF) signalling, a cytokine highly expressed in both RA synovial fluid and tissue
and on circulating mononuclear cells from RA patients. Given its prominent role in macrophage
differentiation and activation, it has been suggested that GM-CSF inhibition may represent a favourable
therapeutic approach to treat RA. Indeed, early phases of clinical trials evaluating anti-GM-CSF therapy
demonstrated its potential clinical benefit in RA patients [60].
Finally, other enriched targeted pathways included interleukin-5 (IL-5) and interleukin-3 (IL-3)
signalling. IL-5 is known to stimulate B cells’ growth, increasing immunoglobulin secretion,
whereas IL-3 is a potent inducer of RANKL expression in human basophils and an important
role for this molecule in the early phase of collagen-induced arthritis has been demonstrated [61].
3.4. LncRNA RP11-498C9.15 Targets Highly Connected Genes in the RA Transcriptome
Since it is well known that the targeting of highly connected genes can have a more pronounced
impact on the development of a disease than the modulation of transcripts that show no functional
interactions, we wanted to verify that RP11-498C9.15 could control highly interacting genes in the
RA transcriptome.
With this purpose in mind, we first built a protein-protein interaction (PPI) network that included
all the experimentally validated functional interactions among the protein products of the 942 modulated
genes in RA; thereafter, we performed a modular analysis to find the areas of the network in which the
most highly connected genes were clustered. The obtained network included 755 nodes (genes) and
2496 edges (pairs of interactions) and exhibited a good enrichment p-value (p < 1.0e−16) (Figure 2).
Interestingly, the topological analysis of the PPI network revealed that, via their miRNAs targets,
RP11-498C9.15 was connected to genes with a high degree of connectivity (Figure 3), whereas the
modular analysis highlighted the presence of six modules (Table S5) that included genes regulated by
RP11-498C9.15 (Table 6).
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Figure 2. Protein-protein interaction (PPI) network of genes modulated in RA patients.
Figure 3. Graphical representation of connections among RP11-498C9.15 and modulated genes in the
PPI network. Differentially expressed genes in RA patients are ordered around a circle based on their
degree of connectivity (number of edges).
In module M1, CUL3, HNRNPA0 and SOCS3 were targeted and, notably, the latter has been found
to be upregulated in RA fibroblast-like synoviocytes and RA PBMCs [62]. In module M2, RP11-498C9.15
targeted ANO6, which is involved in bone mineralization, whereas in module M3, the lncRNA targeted
ATP5G2, TERF2 and the abovementioned PTGES2, which, as previously mentioned, operates the
conversion of prostaglandin H2 to prostaglandin E2.
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Table 6. Modulated genes included in the six modules that are targeted by RP11-498C9.15.
Module miRNAs Gene
M1 hsa-miR-23c (1.56 up) CUL3
hsa-miR-23b-3p (2.06 up) CUL3
hsa-miR-23a-3p (1.74 down) CUL3
hsa-miR-221-3p (2.34 up) HNRNPA0
hsa-miR-302c-3p (2.48 down) SOCS3
hsa-miR-221-3p (2.34 up) SOCS3
M2 hsa-miR-372-3p (1.63 up) ANO6
M3 hsa-miR-101-3p (1.80 up) ATP5G2
hsa-miR-137 (2.54 up) PTGES2
hsa-miR-101-3p (1.80 up) TERF2
hsa-miR-613 (1.55 down) TERF2
hsa-miR-221-3p (2.34 up) TERF2
hsa-miR-206 (2.04 up) TERF2
M4 hsa-miR-4735-3p (2.53 up) ATM
hsa-miR-101-3p (1.80 up) NACA
hsa-miR-137 (2.54 up) PCGF5
hsa-miR-101-3p (1.80 up) SEL1L
hsa-miR-101-3p (1.80 up) SURF4
hsa-miR-613 (1.55 down) THBS1
hsa-miR-4735-3p (2.53 up) THBS1
hsa-miR-221-3p (2.34 up) THBS1
hsa-miR-206 (2.04 up) THBS1
hsa-miR-18b-5p (1.67 down) THBS1
hsa-miR-18a-5p (2.32 up) THBS1
hsa-miR-613 (1.55 down) VPS45
hsa-miR-206 (2.04 up) VPS45
M5 hsa-miR-137 (2.54 up) AKT2
hsa-miR-613 (1.55 down) JUND
hsa-miR-206 (2.04 up) JUND
hsa-miR-520e (1.83 down) RELA
hsa-miR-520d-3p (1.92 down) RELA
hsa-miR-520c-3p (1.52 down) RELA
hsa-miR-520b (1.70 down) RELA
hsa-miR-520a-3p (1.50 down) RELA
hsa-miR-372-3p (1.63 up) RELA
hsa-miR-302e (2.18 down) RELA
hsa-miR-302d-3p (1.84 down) RELA
hsa-miR-302c-3p (2.48 down) RELA
hsa-miR-302b-3p (1.66 down) RELA
hsa-miR-302a-3p (1.58 down) RELA
hsa-miR-137 (2.54 up) SRC
M6 hsa-miR-23c (1.56 up) STX12
hsa-miR-23b-3p (2.06 up) STX12
hsa-miR-23a-3p (1.74 down) STX12
hsa-miR-206 (2.04 up) STX12
Module M4 included seven targeted genes, ATM, NACA, PCGF5, SEL1L, SURF4, THBS1 and
VPS45, while in module M5, AKT2, JUND, RELA and SRC were targeted. In this regard, we have to
mention that AKT2 induces the proliferation and migration of RA fibroblast-like synoviocytes [63],
JUND can contribute to bone erosion [64], RELA is a key component of the NF-kB transcription factor
crucially involved in RA [65], and SRC has bone resorptive properties.
In module M6, STX12, which is involved in autophagy, was targeted.
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The level of expression of RP11-498C9.15, selected miRNA and gene targets were validated by
RT-PCR (Figure S1). Statistically significant differences between patients and healthy subjects were
found in the expression levels of all the tested transcripts.
4. Discussion
RA is an inflammatory chronic autoimmune disease and its pathogenesis is influenced by genetic,
environmental and epigenetic factors [1]. LncRNAs are key components of the epigenetic machinery
that can regulate chromatin remodelling and gene expression by interacting with other epigenetic
factors and with genes. Interestingly, lncRNAs seem to be involved in the development of several
autoimmune diseases [3].
In the present work, we simultaneously profiled a large number of coding and non-coding
transcripts in the same cohort of early-phase-RA patients in order to identify the lncRNAs that most
probably shape the outcomes of crucial biological processes strictly associated with RA pathogenesis.
The criteria adopted to select deregulated lncRNAs in RA rely on the analysis of experimentally
validated functional interaction among coding and non-coding partners of the RA transcriptome.
Using this approach, six lncRNAs were filtered; such lncRNAs, via their miRNA targets, can modulate
differentially expressed genes in RA patients.
Since it is now a common notion that disease can be explained in terms of molecular pathways’
perturbation, we performed a pathway enrichment analysis of all modulated genes that were targeted by
the six selected lncRNAs. Through this analysis we observed that transcripts targeted by RP11-498C9.15,
unlike transcripts targeted by the other five lncRNAs, showed a good coverage of pathways significantly
modulated in the disease. Indeed, RP11-498C9.15 was able to target almost all the signalling pathways
in which genes modulated in RA samples are involved, thus showing the best correlation to the
RA transcriptome.
Notably, RP11-498C9.15 targeted meaningful signalling pathways that have been already associated
with RA and RA-fibroblast-like synoviocytes’ behaviours, while the other selected lncRNAs targeted
only a few pathways that were also modulated by RP11-498C9.15.
By analysing the whole pattern of functional interactions among the modulated genes, we could
observe that RP11-498C9.15 targeted modules of the most highly connected genes in the RA interactome,
which are believed to be principally involved in the disease onset.
Also, for this reason, although we cannot exclude the involvement of the other selected lncRNAs,
we believe that RP11-498C9.15 may play a crucial role in the pathogenesis of RA.
We are aware that a limitation of this work is the small number of samples analysed, but this
is mainly due to the difficulty of recruiting RA patients in the early phase of the disease and in the
absence of any treatment.
We believe that, especially if our results are confirmed on a larger cohort of patients, the lncRNA
RP11-498C9.15 deserves to be identified as a candidate in the design of novel therapeutic strategies
in RA.
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